Open Access Open Access  Restricted Access Subscription Access

Comparative Cytotoxic Assay of Pharmaceutical Drug Compounds

Ahunun I. Frances


The drug compounds under assay have been previously employed for the treatment of restenosis and other diabetic complications. They show potential for the treatment of diseases such as rheumatoid arthritis, atherosclerosis, cirrhosis, fibrosis, cancer and autoimmune diseases. The cytotoxicity of these compounds have been established, however this study brings all three compounds together for a comparative analysis. The importance of research work into cancer treatment cannot be overemphasized with the annual incidence of mortality due to the disease. This study is done in hindsight, bringing back previous drugs with the aim of optimizing characteristic individual properties. Compound A showed significantly higher cytotoxicity than compound B and C, although equally effective to a lesser degree. The different levels of activity can be optimized considering potency, selectivity and toxicity effects.

Full Text:



Hanahan D, Weinberg R.A (Jan 2000), “The hallmarks of cancer” Cell, Volume 100, Issue 1, pp. 57−70.

Hodgson S (Jan 2008), “Mechanism of inherited cancer susceptibility”, Journal of Zhejiang University, Volume 9, Issue 1, pp. 1−4.

William J H, Maurie M, Robert C Y,Carlos A P,Marcus E R, Richard R B,William A M, (2005), “Principles and practice of gynecologic oncology”, Baltimore, Md: Lippincott Williams & Willkins, ISBN 0-7817-4689-2 [3]

Collin .P. D, Jai .P. S, Collin .W. S, (1994), Pharmaceutical Compounds, US 5284868 A.

Samantha .J.A, (1996), Pharmaceutical Compounds, US 5514706 A.


  • There are currently no refbacks.